Navigation Links
Greenphire CEO Sam Whitaker speaks on Sunshine Act and Clinical Trial Payments
Date:12/4/2012

KING OF PRUSSIA, Pa., Dec. 4, 2012 /PRNewswire-iReach/ -- Greenphire CEO Sam Whitaker spoke at the Sunshine Act and Aggregate Spend Bootcamp on the implications of the Physician Sunshine Act for the management of clinical trial payments and on advances in technology which streamlines financial reporting required to comply with the Act. 

The discussion focused on how pharmaceutical, biotech, and medical device companies can use technology to gather and report on required data on clinical trial payments, which present a particular tracking challenge because each clinical trial may involve a complex series of payments made to multiple physician investigators across multiple clinical sites.  To further complicate matters, payments may be made directly or by third parties like Contract Research Organizations (CROs).  Sam's discussion also focused on best practices in preparing for the Act and on the ancillary benefits to sponsor organizations of implementing data aggregation technologies across clinical trials, which include increased automation, tracking, and accountability, and reduced costs and risk.

The presentation took place on Tuesday, December 4, 2012 in Philadelphia, PA.  The Sunshine and Aggregate Spend Bootcamp is an intensive, hands-on seminar intended to prepare pharmaceutical and medical device companies for the requirements of complying with aggregate spend reporting under the Physician Sunshine Act.

About Greenphire

Greenphire is the industry's leading provider of clinical payment technology, designed to change the way research professionals work. We leverage our proprietary workflow automation and advanced web‐based payment technologies to help our clients improve operational efficiency, reduce costs, mitigate regulatory risks, increase subject retention and compliance, and produce quantifiable results that improve clinical operations and strategic planning. Learn more at www.greenphire.com.

Media Contact: Shana Jalbert Greenphire, (215) 948-9260, shana.jalbert@greenphire.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Greenphire
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Autism Speaks announces the release of new genetic data for researchers
2. Autism Speaks and SAGE® Labs develop rat models for translational autism research
3. Autism Speaks awards nearly $2.9 million to fund autism research
4. Autism Speaks awards $1.1 million to fund high priority studies
5. Plant DNA speaks English, identifies new species
6. Sunshine, biofuel and the tides, oh my!
7. TESARO and Virginia G. Piper Cancer Center announce first patient in clinical trial of TSR-011
8. Clinical hypnosis can reduce hot flashes after menopause, Baylor study shows
9. BioLife Solutions Products Now Used in More than 50 Clinical Trial-Stage Cellular Therapies
10. Advanced Clinical Joins MedNet Solutions iMedNet Partner Program
11. New Market Forecasts Available for Critical Global Biotechnology Testing and Screening Markets: Molecular Diagnostics, Hematology, Clinical Chemistry and Nucleic Acid Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... its 2016 Annual Report on Form 10-K on Thursday April 13, ... ... the Investor Relations section of the Company,s website at http://www.nxt-id.com ... http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, ... secure authentication solutions, today announced that it has ... Advanced Research Projects Activity (IARPA) to develop next-generation ... program. "Innovation has been a driving ... Thor program will allow us to innovate and ...
(Date:4/11/2017)... 2017 NXT-ID, Inc. (NASDAQ:   NXTD ... the appointment of independent Directors Mr. Robin D. Richards ... of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief ... to their guidance and benefiting from their considerable expertise as ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ... Administration (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal ... the treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and ...
(Date:10/10/2017)... ... October 10, 2017 , ... Dr. Bob Harman, founder and CEO ... Diego Rotary Club. The event entitled “Stem Cells and Their Regenerative ... attendees. Dr. Harman, DVM, MPVM was joined by two human doctors: Peter B. ...
(Date:10/10/2017)... , ... October 10, 2017 , ... ... of 13 prestigious awards honoring scientists who have made outstanding ... a scheduled symposium during Pittcon 2018, the world’s leading conference and exposition for ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... of medical marijuana products targeting the needs of consumers who are incorporating medical ... takes place in Phoenix, Arizona. , As operators of two successful Valley dispensaries, ...
Breaking Biology Technology: